Skip to content

Global Oncology preclinical
DRUG Intelligence

2024

Intelligence Report to Cover 1250 Preclinical Stage Companies

Released MAy 2024

1250

Oncology Pre Clinical Stage Drug Companies

First of its kind Report to provide Complete Insights on Early Stage Drug Discovery and Provides Insights on 1250 Active, well-funded Oncology Preclinical Stage Companies.

Report Covers Complete Insights on Early Stage Cancer Drug Intelligence

COMPANIES * MOLECULES * INDICATIONS * TECHNOLOGIES * DEALS * FUNDING

Specially designed to identify active early stage researchers, with new ideas capable of changing the face of drug discovery. Report clearly outlines young entrepreneurs established in recent years; having valid funding, clear demarked cancer targeting pipeline and their proprietary Technologies.

Report covers largest set of authentic early stage oncology drug developers worldwide with early stage molecules available for partnering and is a perfect tool to identify new partnering leads.

largest coverage Guranteed

providing intelligence at fingertips

Countries
1

34 Countries’ Drug Developers Insights

Drug developers
1

Preclinical Stage Oncology Companies Profiled 

Molecules in Development
200 +

Individual Drug Mechanism of Action & Drug Target

Cancer Targets
1 +

Covers complete Emerging Cancer Drug Targets Details with Numerous Technologies

Prebuild Intelligence

identify Emerging Technologies and Molecules

Molecule Type
The Report Highlights Preclinical Stage Drug Developers Developing
Cellular Therapeutics
172 Early Stage / Startups Developing – CAR-T / CAR-NK & other Cell based Therapies Targeting Cancer.
(Complete Insights covering Companies, Technologies, Deals, Funding & Molecules in Development)
Monoclonal Antibodies
152 Early Stage / Startups Developing Monoclonal Antibodies against Tumor Antigens.
(Complete Insights covering Companies, Technologies, Deals, Funding & Molecules in Development)
Bispecific Antibodies &
Bispecific T Cell Engagers
62 Early Stage / Startups Developing Bispecific Antibodies & Bispecific T Cell Engagers.
(Complete Insights covering Companies, Technologies, Deals, Funding & Molecules in Development)
Antibody Drug Conjugates
68 Early Stage / Startups Developing Antibody Drug Conjugates targeting Cancer.
(Complete Insights covering Companies, Technologies, Deals, Funding & Molecules in Development)
Cancer Vaccines
84 Early Stage / Startups Developing Vaccines against Cancer.
(Complete Insights covering Companies, Technologies, Deals, Funding & Molecules in Development)
Kinase Inhibitors
97 Early Stage / Startups Developing Small Molecule Kinase Inhibitors Targeting Cancer
(Complete Insights covering Companies, Technologies, Deals, Funding & Molecules in Development)
Targeted Protein Degraders
59 Early Stage / Startups Developing Small Molecule Targeted Protein Degraders against Cancer
(Complete Insights covering Companies, Technologies, Deals, Funding & Molecules in Development)
Cancer Targeting Radiopharmaceuticals
24 Early Stage / Startups Developing Cancer Targeting Radiopharmaceuticals.
(Complete Insights covering Companies, Technologies, Deals, Funding & Molecules in Development)
Extracellular Vesicles (EVs)
Derived Cancer Targeting Drugs
20 Startups Developing Exosome & Microvesicles Based Cancer Targeting Drugs.
(Intelligence covering Companies, Technologies & Molecules in Development)
Microbiome & Engineered Bacteria Based
Cancer Targeting Drugs
28 Startups Developing Microbiome & Engineered Bacteria Based Cancer Targeting Drugs
(Intelligence covering Companies, Technologies & Molecules in Development)

intelligence supercharged

956 pages full of Insights

Knowledge Multiplier

Better Than Others

Comparisons
Preclinical Oncology Drug Intelligence 2022
Other Intelligence Sources
Pre-Clinical Stage Oncology Drug Developers
1250 Active Companies
(Well Funded with clear defined early stage Pipeline)
400-600 Companies
(with many inactive and other domain companies)
Worldwide Coverage
33 Countries Included
(53% USA, 28% Europe, 14% Asia and 5% ROW)
Mainly United States and Europe Covered
Oncology Drugs in Development
1400+ Onco Targeting Drugs in Active Development
(1400+ Preclinical Stage Drugs, with their Targets and mechanism of Action)
400 – 600 Onco Early Stage Drugs
(mainly focuses on Clinical Stage molecules)
Bio-Partnering Details
800+ Oncology Deals complete details.
(Complete coverage on Oncology focused Deals, Funding & Partnering Activities, since company’s incorporation)
Limited to Database / Resource Subscribed to.
(Also it may require mapping of events between two or more different resources and filtering Onco Linked Deals).
Single Step Connect
Over 2000+ Key Decision Makers in 1250 Companies
with valid emails and LinkedIn Accounts Links for one click contact. (Further CRMS Development Support is also available)
No Customized Solution Available in Market
(Needs months of hard team work to prepare authentic business development tool.

Free Further Customization on This Report

Limited Time Offer  Instand Download

Trusted by

Over 350+ Companies